Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism.

@article{Li2010RituximabinducedLN,
  title={Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism.},
  author={Szu-Chin Li and Yi-chun Chen and Andrew M Evens and C -C Lee and Hui-Fen Liao and Chi-Chia Yu and Ya-Ting Tung and Yu-chieh Su},
  journal={American journal of hematology},
  year={2010},
  volume={85 10},
  pages={810-2}
}
Rituximab is a commonly utilized treatment agent for B-cell lymphoma. Late onset neutropenia (LON) has been identified as a complication associated with rituximab, primarily in conjunction with hematopoietic stem cell transplantation (HSCT). Scant data exists regarding rituximab-related LON outside the spectrum of HSCT, including newly-diagnosed lymphoma… CONTINUE READING